证券代码：603259 证券简称：药明康德 公告编号：临 2025-061 无锡药明康德新药开发股份有限公司 关于公司下属全资子公司之间股权划转的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 注册资本： 人民币 1,245,720 万元 一、股权划转概述 为优化组织结构，明确国内实体经营企业和控股平台企业的分工及权责，无 锡药明康德新药开发股份有限公司（以下简称"公司"）根据对子公司业务和职 责梳理后，决定将部分子公司股权划转至公司新设国内控股型全资子公司。 现公司拟将上海药明康德新药开发有限公司（以下简称"上海药明"）持有 权益的上海合全药业股份有限公司（以下简称"标的公司"）98.9%的股份全部 划转给药明康德（上海）医药研发有限公司（以下简称"药明研发"，前述划转 事项以下简称"本次股权划转"）。本次股权划转完成后，药明研发将直接持有 标的公司 98.9%股份。本次股权划转不涉及公司合并报表范围变化，不改变标的 公司实质经营活动，不会对标的公司主体利润和整体权益产生任何影响。 本次股权划转所涉事项在公司董事会审议 ...

证券代码：603259 证券简称：药明康德 公告编号：2025-062 无锡药明康德新药开发股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东大会召开日期：2025年9月23日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 (一) 股东大会类型和届次 2025年第二次临时股东大会 至2025 年 9 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 ...

无锡药明康德新药开发股份有限公司 2025 年第二次临时股东大会 会议材料 二〇二五年九月 无锡药明康德新药开发股份有限公司 股东大会会议须知 为了维护全体股东的合法权益、保障股东依法行使股东权利，确保股东大会 的正常秩序和议事效率，根据中国证券监督管理委员会（以下简称"中国证监会"） 《上市公司股东会规则》及《无锡药明康德新药开发股份有限公司章程》《无锡 药明康德新药开发股份有限公司股东大会议事规则》，特制订本须知。 一、公司设董事会办公室，具体负责大会有关程序方面的事宜。 二、会议期间全体出席会议人员应以维护股东合法权益，确保大会正常秩序， 提高议事效率为原则，认真行使法定权利并履行法定职责。 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股东（或 其授权代表）、董事、监事、董事会秘书、高级管理人员、聘请的律师和董事会 邀请参会的人员外，公司有权依法拒绝其他人士入场。 四、为及时、准确统计出席股东大会的股东人数及所持有表决权的股份数量， 出席会议的股东（或其授权代表）请按照股东大会通知中载明的会议登记办法在 会议召开前向董事会办公室办理签到登记手续。 五、股东（或其授权代表）依法享有发言权、咨 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-058 无锡药明康德新药开发股份有限公司 第三届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 8 月 28 日向本公司全体董事发出会议通知及会议材料，以通讯表决方式 于 2025 年 9 月 2 日召开第三届董事会第二十五次会议。本次董事会会议应出席 董事 11 人，实际出席董事 11 人，会议由董事长 Ge Li（李革）召集。本次董事 会符合《中华人民共和国公司法》和《无锡药明康德新药开发股份有限公司章程》 （以下简称"《公司章程》"）关于召开董事会会议的规定。 二、董事会会议审议情况 （一）审议通过《关于取消监事会、变更公司注册资本、修改公司章程并办 理工商变更登记的议案》 同意公司取消监事会，于经修订后的《公司章程》生效之日，《无锡药明康 德新药开发股份有限公司监事会议事规则》同步予以废止；同意公司注册资本由 2,88 ...

Core Viewpoint - The global drug development model has fundamentally shifted from a "solo" approach to a collaborative one, with the rise of the CXO industry accelerating new drug development processes [1] Group 1: CRDMO Model - WuXi AppTec's CRDMO model integrates the entire drug development process from research (R) to development (D) and commercialization (M), allowing the company to capture industry innovation trends and provide downstream business support [2] - The CRDMO model has enabled WuXi AppTec to establish partnerships with over 150 companies in the targeted protein degradation (TPD) field, synthesizing more than 188,000 complex TPD compounds, with over 70 entering preclinical stages and more than 10 in late-stage development [2] Group 2: Operational Efficiency - The integrated CRDMO model facilitates seamless collaboration among multiple teams, reducing costs and project transfer risks, thus enhancing the efficiency of new drug development [3] - WuXi AppTec has expanded its global footprint from a single 650-square-meter lab to nearly 30 R&D and production bases worldwide, optimizing facility utilization and lowering investment costs and risks [4] Group 3: Financial Performance - WuXi TIDES reported a revenue of 5.03 billion yuan in the first half of 2025, reflecting a year-on-year growth of 141.6%, making it one of the fastest-growing segments for WuXi AppTec [5] - The company is also expanding its small molecule production capacity, with projections indicating that the total reactor volume at its Changzhou and Taixing facilities will exceed 4 million liters by the end of 2025 [5] Group 4: Quality and Compliance - WuXi AppTec's global operations adhere to high-quality standards, as evidenced by its two API production bases in Changzhou and Taixing passing FDA inspections without any non-compliance issues [6] Group 5: Workforce and Culture - The company has grown its team from 100 process chemists to over 3,000, enhancing its ability to meet diverse client needs without delays [7] - WuXi AppTec emphasizes its commitment to supporting drug discovery, development, and production, aiming to benefit the industry, clients, and ultimately patients [7]

药明康德成交额达100亿元，现涨2.26%。 ...

Core Insights - On September 1, 28 out of 31 primary industries in the Shenwan index received net financing inflows, with the electronics sector leading at a net inflow of 5.58 billion [1] - Other notable sectors with significant net inflows include telecommunications, non-ferrous metals, power equipment, automotive, and non-bank financials, each exceeding 2 billion in net inflows [1] Industry Summary - The electronics industry topped the list with a net financing inflow of 5.58 billion [1] - Telecommunications, non-ferrous metals, power equipment, automotive, and non-bank financials also showed strong performance with net inflows exceeding 2 billion each [1] Company Summary - A total of 2062 stocks experienced net financing inflows on September 1, with 89 stocks having inflows over 100 million [1] - BYD led individual stocks with a net inflow of 1.401 billion, followed by companies like Xinyi Semiconductor, Zhongji Xuchuang, Zijin Mining, Hanwha, Zhaoyi Innovation, Tongfu Microelectronics, WuXi AppTec, and China Ping An, all exceeding 500 million in net inflows [1]

Group 1 - Major financial institutions like JPMorgan, Citigroup, and Morgan Stanley have recently increased their holdings in H-shares such as CATL, ZTE, and WuXi AppTec, indicating a growing interest in these stocks [1] - JPMorgan's long position in CATL H-shares rose from 5.98% to 6.06%, while Morgan Stanley's increased from 4.96% to 6.05% [1] - The Hong Kong stock market showed strong performance in August, with the Hang Seng Index rising by 1.23% and the Hang Seng Tech Index increasing by 4.06% [3] Group 2 - There is a concern that retail investors often enter the market after institutions have already made their moves, leading to potential losses for these investors [5] - A notable example of institutional behavior is highlighted, where foreign institutions claimed to avoid thematic stocks but were found heavily invested in restructuring concept stocks after earnings reports were released [6] - The concept of "institutional inventory" is introduced as a key indicator of institutional trading activity, suggesting that active participation by institutions can signal future stock performance [9][11] Group 3 - The article emphasizes the importance of understanding the true flow of funds rather than relying on news, which often lags behind actual market movements [14] - It is suggested that retail investors should focus on analyzing data that reveals institutional actions to avoid being misled by superficial news [14] - The conclusion stresses that those who can access and interpret real data will have a competitive advantage in the market [14]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 91,150,340 | | | RMB | | 91,150,340 | | 本月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 2. 股份分類 ...

截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 91,150,340 | | | RMB | | 91,150,340 | | 本月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | -- ...